Futura hails product progress 08/09/2010
Consumer healthcare concern Futura Medical says it expects European approval this year for its CSD500 erection-maintaining condom.
Independent oil & gas exploration company
BlackRock: 11.2%
PGS Ventures: 6.8%
UBS: 5.4%
Gartmore Investment: 4.9%
JPMorgan Asset Management: 3%
| 2009 | 2008 | |
|---|---|---|
| Turnover: | n/a | n/a |
| Pre-tax profit: | $ (1.65m) | $ (0.54m) |
| EPS: | (1.83) c | (2.31) c |
Directors’ Dealings by Jenny Lowe 08/06/2010
Advertisement
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Advertisement
Consumer healthcare concern Futura Medical says it expects European approval this year for its CSD500 erection-maintaining condom.
Dana Petroleum says its shares are worth between £22.70p and £24.65p to support its opposition to Korea National Oil Corporation's bid at £18.
Online antibody distributor Abcam fears public spending cuts might dampen growth after lifting annual pre-tax profits 58.4 per cent to £25.8 million.